title: Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids.
abstract: Triple recycling (i.e., enterohepatic, enteric and local recycling) plays a central role in governing the disposition of phenolics such as flavonoids, resulting in low systemic bioavailability but higher gut bioavailability and longer than expected apparent half-life. The present study aims to investigate the coexistence of these recycling schemes using model bioactive flavonoid tilianin and a four-site perfused rat intestinal model in the presence or absence of a lactase phlorizin hydrolase (LPH) inhibitor gluconolactone and/or a glucuronidase inhibitor saccharolactone. The result showed that tilianin could be metabolized into tilianin glucuronide, acacetin, and acacetin glucuronide, which are excreted into the bile and luminal perfusate (highest in the duodenum and lowest in the colon). Gluconolactone (20 mM) significantly reduced the absorption of tilianin and the enteric and biliary excretion of acacetin glucuronide. Saccharolactone (0.1 mM) alone or in combination of gluconolactone also remarkably reduced the biliary and intestinal excretion of acacetin glucuronide. Acacetin glucuronides from bile or perfusate were rapidly hydrolyzed by bacterial β-glucuronidases to acacetin, enabling enterohepatic and enteric recycling. Moreover, saccharolactone-sensitive tilianin disposition and glucuronide deconjugation, which was more active in the small intestine than the colon, points to the small intestinal origin of the deconjugation enzyme and supports the presence of local recycling scheme. In conclusion, our studies have demonstrated triple recycling of a bioactive phenolic (i.e., a model flavonoid), and this recycling may have an impact on the site and duration of polyphenols pharmacokinetics in vivo.
authors.affiliation: International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
authors.forename: Peimin
authors.initials: P
authors.lastname: Dai
authors.forename: Lijun
authors.initials: L
authors.lastname: Zhu
authors.forename: Feifei
authors.initials: F
authors.lastname: Luo
authors.forename: Linlin
authors.initials: L
authors.lastname: Lu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Liping
authors.initials: L
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Xinchun
authors.initials: X
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Hu
authors.forename: Zhongqiu
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001646:Bile / Q000378:metabolism; D001682:Biological Availability; D047309:Flavones / Q000378:metabolism*; D005419:Flavonoids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005937:Glucaric Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D005942:Gluconates / Q000494:pharmacology; D005966:Glucuronidase / Q000037:antagonists & inhibitors / Q000378:metabolism; D020719:Glucuronides / Q000378:metabolism; D006027:Glycosides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D007413:Intestinal Mucosa / Q000378:metabolism*; D010694:Lactase-Phlorizin Hydrolase / Q000037:antagonists & inhibitors / Q000378:metabolism; D007783:Lactones / Q000494:pharmacology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D047309:Flavones; D005419:Flavonoids; D005942:Gluconates; D020719:Glucuronides; D006027:Glycosides; D007783:Lactones; C426884:tilianin; C009194:saccharolactone; D005966:Glucuronidase; D010694:Lactase-Phlorizin Hydrolase; C023717:acacetin; D005937:Glucaric Acid; C010730:beta-glucono-1,5-lactone